331. Idiopathic multicentric castleman disease
30 clinical trials, 44 drugs (DrugBank: 23 drugs), 30 drug target genes, 148 drug target pathways
Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04585893 (ClinicalTrials.gov) | October 2020 | 10/9/2020 | Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi | LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial | Multicentric Castleman Disease | Drug: Rituximab;Drug: Etoposide | UNC Lineberger Comprehensive Cancer Center | Fogarty International Center of the National Institute of Health | Not yet recruiting | 18 Years | N/A | All | 27 | Phase 2 | Malawi |
| 2 | JPRN-jRCT2071190029 | 25/05/2020 | 09/10/2019 | Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) | Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) | idiopathic multicentric Castleman's disease Castleman's disease | Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily | Kawakami Atsushi | NULL | Recruiting | >= 18age old | Not applicable | Both | 20 | Phase 2 | Japan |
| 3 | NCT03864419 (ClinicalTrials.gov) | October 24, 2019 | 1/3/2019 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda | Burkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell Lymphoma | Biological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: Etoposide | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) | Recruiting | 2 Years | N/A | All | 40 | Phase 1 | Uganda;United States |
| 4 | NCT03933904 (ClinicalTrials.gov) | September 25, 2019 | 29/4/2019 | Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | Castleman Disease;Castleman's Disease, Multicentric | Drug: Sirolimus | University of Pennsylvania | NULL | Recruiting | 18 Years | 80 Years | All | 24 | Phase 2 | United States |
| 5 | NCT03982771 (ClinicalTrials.gov) | January 1, 2019 | 3/5/2019 | BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) | Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Idiopathic Multicentric Castleman's Disease | Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethason | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03043105 (ClinicalTrials.gov) | January 1, 2017 | 31/1/2017 | TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Multicentric Castleman Disease | Drug: Thalidomide, cyclophosphamide and prednisone | Peking Union Medical College Hospital | NULL | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 2 | China |
| 7 | NCT02228512 (ClinicalTrials.gov) | August 15, 2014 | 27/8/2014 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion Lymphoma | Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide | National Cancer Institute (NCI) | NULL | Withdrawn | 18 Years | 99 Years | All | 0 | Phase 1;Phase 2 | United States |
| 8 | NCT02080416 (ClinicalTrials.gov) | July 2014 | 4/3/2014 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors | Non-Hodgkin Lymphoma;Hodgkin Lymphoma;Kaposi Sarcoma;Gastric Cancer;Nasopharyngeal Cancer;EBV;Castleman Disease | Drug: Nelfinavir | Sidney Kimmel Comprehensive Cancer Center | NULL | Terminated | 18 Years | N/A | Both | 1 | Phase 0 | United States |
| 9 | EUCTR2010-022837-27-GB (EUCTR) | 15/02/2013 | 01/08/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04] | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of | |||
| 10 | EUCTR2010-022837-27-BE (EUCTR) | 17/12/2012 | 23/07/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2010-022837-27-ES (EUCTR) | 29/11/2012 | 26/09/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 15.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of | ||
| 12 | EUCTR2010-022837-27-DE (EUCTR) | 21/11/2012 | 19/09/2012 | A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of | ||
| 13 | NCT01552434 (ClinicalTrials.gov) | March 16, 2012 | 7/3/2012 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |
| 14 | NCT01441063 (ClinicalTrials.gov) | September 13, 2011 | 24/9/2011 | Tocilizumab for KSHV-Associated Multicentric Castleman Disease | Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease | Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia | Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC) | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 8 | Phase 2 | United States |
| 15 | NCT01400503 (ClinicalTrials.gov) | April 1, 2011 | 21/4/2011 | A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease | Multicentric Castleman's Disease | Drug: Siltuximab | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 60 | Phase 2 | United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2009-012380-34-GB (EUCTR) | 18/05/2010 | 24/09/2009 | A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease | Multicentric Castleman's disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 78 | Phase 2 | United States;Hong Kong;Taiwan;Spain;Israel;Russian Federation;United Kingdom;India;France;Egypt;Hungary;Canada;Malaysia;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;Norway;New Zealand;China;Korea, Republic of | |||
| 17 | EUCTR2009-012380-34-NL (EUCTR) | 23/03/2010 | 21/10/2009 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | Multicentric Castleman's disease MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 78 | Phase 2 | France;Hungary;Spain;Belgium;Germany;Netherlands;United Kingdom | ||
| 18 | NCT01024036 (ClinicalTrials.gov) | March 18, 2010 | 30/11/2009 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease | Multicentric Castleman's Disease | Drug: Siltuximab;Drug: Placebo;Drug: Best Supportive Care (BSC) | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 79 | Phase 2 | United States;Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Jordan;Poland |
| 19 | EUCTR2009-012380-34-HU (EUCTR) | 18/03/2010 | 15/12/2009 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | Multicentric Castleman's disease MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Janssen Biologics BV | NULL | Not Recruiting | Female: yes Male: yes | 78 | Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain | |||
| 20 | EUCTR2009-012380-34-DE (EUCTR) | 27/01/2010 | 15/10/2009 | A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease | Multicentric Castleman's disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 75 | United Kingdom;France;Hungary;Spain;Belgium;Netherlands;Germany | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2009-012380-34-BE (EUCTR) | 26/01/2010 | 05/10/2009 | A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease | Multicentric Castleman's disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Janssen-Cilag International N.V. | NULL | Not Recruiting | Female: yes Male: yes | 78 | Phase 2 | Hong Kong;United States;Taiwan;Israel;Russian Federation;United Kingdom;India;France;Egypt;Hungary;Canada;Malaysia;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;Norway;New Zealand;China;Korea, Republic of;Spain | ||
| 22 | EUCTR2009-012380-34-FR (EUCTR) | 21/01/2010 | 16/10/2009 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease | Multicentric Castleman's disease MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Centocor BV | NULL | Not Recruiting | Female: yes Male: yes | 75 | Phase 2 | France;Hungary;Spain;Belgium;Netherlands;Germany;United Kingdom | ||
| 23 | EUCTR2009-012380-34-ES (EUCTR) | 21/12/2009 | 08/10/2009 | Estudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDisease | Estudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDisease | enfermedad de Castleman multicéntrica MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease | Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody | Centocor BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain | |||
| 24 | NCT00891280 (ClinicalTrials.gov) | February 2009 | 29/4/2009 | Dose-escalation Study of Oral CX-4945 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma | Advanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple Myeloma | Drug: CX-4945 oral formulation | Cylene Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | Both | 55 | Phase 1 | United States |
| 25 | NCT00361933 (ClinicalTrials.gov) | December 2008 | 8/8/2006 | Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease | Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir | Giant Lymph Node Hyperplasia | Drug: Valganciclovir | University of Washington | Hoffmann-La Roche | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT01183598 (ClinicalTrials.gov) | August 2006 | 13/8/2010 | A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment | Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment | Castleman's Disease | Drug: tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | Both | 3 | Phase 1 | United States |
| 27 | NCT00412321 (ClinicalTrials.gov) | May 2005 | 15/12/2006 | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | Lymphoma, Non-Hodgkin;Multiple Myeloma;Giant Lymph Node Hyperplasia | Drug: CNTO 328 | Centocor, Inc. | NULL | Completed | 18 Years | N/A | Both | 67 | Phase 1 | United States |
| 28 | NCT00092222 (ClinicalTrials.gov) | October 28, 2004 | 21/9/2004 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity | Lymphoproliferative Disorder;HHV-8;Malignancy;HIV | Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only | National Cancer Institute (NCI) | NULL | Recruiting | 12 Years | N/A | All | 72 | Phase 2 | United States |
| 29 | NCT00127569 (ClinicalTrials.gov) | May 2003 | 4/8/2005 | Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy | Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) | HIV Infections;Giant Lymph Node Hyperplasia | Drug: Rituximab | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche | Terminated | 18 Years | N/A | Both | 25 | Phase 2 | NULL |
| 30 | NCT00002652 (ClinicalTrials.gov) | May 1995 | 1/11/1999 | Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease | A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE | Multiple Myeloma and Plasma Cell Neoplasm | Drug: suramin | University of Arkansas | National Cancer Institute (NCI) | Completed | 18 Years | N/A | Both | Phase 2 | United States |